Preview

Пульмонология

Расширенный поиск

Клиническая эффективность формотерола при отсутствии ответа на сальметерок

Полный текст:

Об авторах

Д. Коттакис
Novartis Respiratory Reseach Centre
Великобритания


Р. Вудс
Novartis Pharma AG Basel
Швейцария


В. Ле Гросс
Novartis Pharma SA
Франция


Д. Делла Сьоппа
Novartis Respiratory Reseach Centre
Великобритания


Список литературы

1. Campbell L.M., Anderson J., Paraschchak M.R. et al. A comparison of the efficacy of long-acting p2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group. Respir. Med. 1999; 93: 236—244.

2. Vervloet D., Ekstrom Т., Pela R. et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Ibid. 1998; 92: 836—842.

3. Redington A.E., Rees P.J. Long-acting inhaled p2-agonists in the management of asthma: recent advances and current recommendations. Int. J. Clin. Pract. 1998; 52(7): 482—486.

4. Wallin A., Sandstorm Т., Rosenhall L., Melander B. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611—614.

5. van Noord J.A., S treets J.J., Raaijmakers S.A.M. et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 1996; 9: 1684—1688.

6. Palmqvist М., Persson G., L azer L. et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Ibid. 1997; 10: 2484—2489.

7. Ulrik C.S., Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Ibid. 1994; 7: 1003—1005.

8. Bartuschka B., Querfert H., Ortland C. et al. Formoterol Turbuhaler shows bronchodilating efficacy in patients not responding to salmeterol diskus. Am. J. Respir. Crit. Care Med. 2000; 161 (3): A 190.

9. Noppen M., Vincken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration 2000; 67 (1): 112—113.

10. Bousquet J., Meziane H., Le Gros V., Bourdeux I. Efficacite du formoterol chez des asthmatiques equilibres de facon non optimale par le salmeterol. Rev. Mai. Respir. 2001; 18 (1): S31.

11. Andersen G.P. Formoterol: pharmacology, molecular basis of antagonism, and mechanism of long duration of a highly potent and selective p9-adrenoceptor agonist bronchodilator. Life Sci. 1993; 52: 2145—2160.

12. Green S.A., Spasoff A.P., Coleman R.A. et al. Sustained activation of a G-protein-coupled receptor via anchored agonist binding. J. Biol. Chem. 1996; 271 (39): 24029—24036.

13. Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.

14. Molimard M., Naline E., Zhang Y. et al. Long- and short-acting p2-adrenoceptor agonists interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.

15. Van Veen A., Weller F.R., Wierenga E.A. et al. Regular use of long-acting p2-adrenoceptor agonists attenuates the bronchoprotective efficacy of short-acting p2-adrenoceptor agonists in asthma. Br. J. Clin. Pharmacol. 2000; 50: 485P—499P.

16. Hancox R.J., Sears M.R., Taylor D.R. Polymorphism of the p2-adrenoceptor and the response to long term P2-agonist therapy in asthma. Eur. Respir. J. 1998; 11: 589—593.

17. Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337 (20): 1405—1411.

18. Bourns D., Bachlitzanakis N., Kottakis J. et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur. Respir. J. 1999; 14 (3): 627—632.

19. Greening A. P., Ind P.W., Northfie ld M., S haw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen&Hanburys UK Study Group. Lancet 1994; 344: 219—224.

20. Hancox R.J., Stevens D.A., Adcock A. M. et al. Effects of inhaled p-agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999; 54: 488—492.

21. Taylor D.R., Hancox R.J. Interactions between corticosteroids and p-agonists. Ibid. 2000; 55: 596—602.

22. Scarceriaux V., Pelaprat D., Forgez P. et al. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. Endocrinology 1995; 136: 2554—2560.

23. Peters M.J., Adcock I.M., Brown C.R. et al. p-adrenoceptor agonists interfere with glucorticoid receptor DNA binding in rat lung. Eur. J. Pharmacol. 1995; 289: 275—281.


Для цитирования:


Коттакис Д., Вудс Р., Ле Гросс В., Делла Сьоппа Д. Клиническая эффективность формотерола при отсутствии ответа на сальметерок. Пульмонология. 2001;(4):98-102.

For citation:


Kottakis J., Woods R., Le Gross V., Della Cioppa G. Clinical efficiency of formoterol when there is no response to salmeterol. PULMONOLOGIYA. 2001;(4):98-102. (In Russ.)

Просмотров: 5


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)